Myeloma2018 Session I

 

Clinical Genomics

In session I of Myeloma2018, Suzanne Trudel, MD, FRCPC, Jens Lohr, MD, PhD, Angela Dispenzieri, MD, Ola Landgren, MD, PhD, and Daniel AuClair, PhD, provide updates on important, non-invasive genome profiling techniques to determine key markers in patients with multiple myeloma. Clinical trial results are discussed, as are the effectiveness of techniques such as cell-free disease assessment, MRD testing, and V(D)J based MRD tracking.

Presentations
Cell-free DNA
Suzanne Trudel, MD, FRCPC
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
8 September, 2018

Suzanne Trudel, MD, from the Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, speaks about cell-free DNA.

Cell-free Disease Assessment
Jens Lohr, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
8 September, 2018

Jens Lohr, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, talks about cell-free disease assessment.

MRD Detection by Mass Spectrometry and Monoclonal Proteins
Angela Dispenzieri, MD
Mayo Clinic, Rochester, MN
8 September, 2018

Angela Dispenzieri, MD, from the Mayo Clinic, Rochester, MN, discusses the MRD detection method of mass spectrometry, and monoclonal proteins.

V(D)J Based MRD Tracking: the MSKCC Experience
Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY
8 September, 2018

Ola Landgren, MD, PhD, from the Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the MSKCC experience on V(D)J based MRD tracking in multiple myeloma.

Testing Precision Medicine in Multiple Myeloma
Daniel AuClair, PhD
Multiple Myeloma Research Foundation, Norwalk, CT
8 September, 2018

Daniel AuClair, PhD, from the Multiple Myeloma Research Foundation, Norwalk, CT, discusses precision medicine tests in multiple myeloma.